P90RSK IN COMBINATION WITH RAF/ERK/MEK

摘要

The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer. In particular, the disclosure relates to the combined use of an inhibitor of p90RSK and an inhibitor of another protein of the MAPK/ERK-pathway in the treatment of KRAS-, NRAS-or BRAF-mutated cancer, in particular in NRAS mutated melanoma.